Chronic Myeloid Leukemia: Beyond BCR-ABL1 (Q58102326)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370478%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

title

Chronic Myeloid Leukemia: Beyond BCR-ABL1 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370478%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

1 reference

1 reference

chronic myeloid leukemia

1 reference

Ting Zhou

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370478%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

L Jeffrey Medeiros

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370478%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Shimin Hu

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370478%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

language of work or name

English

0 references

publication date

1 December 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370478%20AND%20SRC:MED&resulttype=core&format=json

Current hematologic malignancy reports

30 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370478%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370478%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370478%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

page(s)

435-445

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370478%20AND%20SRC:MED&resulttype=core&format=json

Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants

30 April 2020

cites work

1 reference

12 December 2020

Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene

1 reference

12 December 2020

Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients

1 reference

12 December 2020

The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc

1 reference

12 December 2020

Jak-STAT signaling induced by the v-abl oncogene

1 reference

12 December 2020

Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression

1 reference

12 December 2020

Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia.

1 reference

12 December 2020

Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis

1 reference

12 December 2020

BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.

1 reference

12 December 2020

Stat6 is required for mediating responses to IL-4 and for development of Th2 cells.

1 reference

12 December 2020

Abberant cytogenetic evolution pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-alpha

1 reference

12 December 2020

Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia

1 reference

12 December 2020

PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl

1 reference

12 December 2020

P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members

1 reference

12 December 2020

BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner

1 reference

12 December 2020

c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia

1 reference

12 December 2020

Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance

1 reference

12 December 2020

The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity

1 reference

12 December 2020

Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants.

1 reference

12 December 2020

Molecular evolution of chronic myeloid leukaemia

1 reference

12 December 2020

Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells

1 reference

12 December 2020

Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.

1 reference

12 December 2020

Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer

1 reference

12 December 2020

A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9

1 reference

12 December 2020

Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.

1 reference

12 December 2020

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase

1 reference

12 December 2020

The biology of CML blast crisis

1 reference

12 December 2020

Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.

1 reference

12 December 2020

BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks

1 reference

12 December 2020

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

1 reference

12 December 2020

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

12 December 2020

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

1 reference

12 December 2020

Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia

1 reference

12 December 2020

Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia

1 reference

12 December 2020

Structural Basis for the Cytoskeletal Association of Bcr-Abl/c-Abl

1 reference

12 December 2020

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia

1 reference

12 December 2020

A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation

1 reference

12 December 2020

Gene expression changes associated with progression and response in chronic myeloid leukemia

1 reference

12 December 2020

Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia

1 reference

12 December 2020

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

1 reference

12 December 2020

Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR.

1 reference

12 December 2020

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

1 reference

12 December 2020

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

1 reference

12 December 2020

Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis

1 reference

12 December 2020

Chronic myeloid leukaemia as a model of disease evolution in human cancer

1 reference

12 December 2020

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

1 reference

12 December 2020

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells

1 reference

12 December 2020

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

1 reference

12 December 2020

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

1 reference

12 December 2020

Transformation of polycythemia vera to chronic myelogenous leukemia

1 reference

12 December 2020

Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia

1 reference

12 December 2020

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

1 reference

12 December 2020

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase

1 reference

12 December 2020

Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia

1 reference

12 December 2020

Crk and CrkL adaptor proteins: networks for physiological and pathological signaling

1 reference

12 December 2020

Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation

1 reference

12 December 2020

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

1 reference

12 December 2020

Immunocytochemical study of Bcr and Bcr-Abl localization in K562 cells.

1 reference

12 December 2020

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

1 reference

12 December 2020

BCR-ABL kinase is dead; long live the CML stem cell

1 reference

12 December 2020

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

1 reference

12 December 2020

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases

1 reference

12 December 2020

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance

1 reference

12 December 2020

Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia

1 reference

12 December 2020

Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B‐lymphoblastic leukemia in the era of tyrosine kinase inhibitors

1 reference

12 December 2020

MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.

1 reference

12 December 2020

Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia

1 reference

12 December 2020

Molecular pathways: BCR-ABL.

1 reference

12 December 2020

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

1 reference

12 December 2020

Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population

1 reference

12 December 2020

How I treat CML blast crisis

1 reference

12 December 2020

Pushing the limits of targeted therapy in chronic myeloid leukaemia.

1 reference

12 December 2020

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

1 reference

12 December 2020

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

1 reference

12 December 2020

Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond

1 reference

12 December 2020

Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era.

1 reference

12 December 2020

Blast crisis Ph+ chronic myeloid leukemia with NUP98/HOXA13 up-regulating MSI2.

1 reference

12 December 2020

Reply to H. Kantarjian et al.

1 reference

12 December 2020

Rare but authentic Philadelphia-positive acute myeloblastic leukemia: two case reports and a literature review of characteristics, treatment and outcome

1 reference

12 December 2020

Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia

1 reference

12 December 2020

Philadelphia chromosome positive pre-T cell acute lymphoblastic leukemia: a rare case report and short review

1 reference

12 December 2020

1 reference

12 December 2020

Chronic myelogenous leukemia in patients with MPL or JAK2 mutation-positive myeloproliferative neoplasm.

1 reference

12 December 2020

Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors

1 reference

12 December 2020

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

1 reference

12 December 2020

Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia

1 reference

12 December 2020

CEBPA mutation in a case of chronic myeloid leukemia presenting in myeloid blast crisis

1 reference

12 December 2020

Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

1 reference

12 December 2020

Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy

1 reference

12 December 2020

Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients

1 reference

12 December 2020

Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics

1 reference

12 December 2020

Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia

1 reference

12 December 2020

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

1 reference

12 December 2020

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia.

1 reference

12 December 2020

The Role of Mutation Testing in Patients with Chronic Myeloid Leukemia in Chronic Phase after Imatinib Failure and Their Outcomes after Treatment Modification: Single-institutional Experience Over 13 Years

1 reference

12 December 2020

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy

1 reference

12 December 2020

Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

1 reference

12 December 2020

Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome

1 reference

12 December 2020

10.1007/S11899-018-0474-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370478%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

1 reference